Difference between revisions of "Off-label"
Jump to navigation
Jump to search
(As of September 25, 2022, a total of 2,719 decisions (2,250 federal) have referenced the term "off-label".) |
(more) |
||
| Line 3: | Line 3: | ||
Estimates are that 21% of all prescriptions are off-label, and an even higher percentage of 36.2% of medications in intensive care units are off-label. | Estimates are that 21% of all prescriptions are off-label, and an even higher percentage of 36.2% of medications in intensive care units are off-label. | ||
| − | As of September 25, 2022, a total of 2,719 decisions (2,250 federal) have referenced the term "off-label". | + | As of September 25, 2022, a total of 2,719 decisions (2,250 federal) have referenced the term "off-label". Of those, only 231 decisions (196 federal) discuss the FDA in proximity with the "off-label" term, and many of those cases are class action product liability cases. |
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 19:20, September 25, 2022
An off-label use of a drug means using an FDA-approved drug for an unapproved use. It is estimated that
Estimates are that 21% of all prescriptions are off-label, and an even higher percentage of 36.2% of medications in intensive care units are off-label.
As of September 25, 2022, a total of 2,719 decisions (2,250 federal) have referenced the term "off-label". Of those, only 231 decisions (196 federal) discuss the FDA in proximity with the "off-label" term, and many of those cases are class action product liability cases.